Compass Therapeutics, Inc. (NASDAQ:CMPX) Receives Average Rating of “Moderate Buy” from Brokerages

Shares of Compass Therapeutics, Inc. (NASDAQ:CMPX) have received a consensus rating of “Moderate Buy” from the fifteen research firms that are presently covering the firm, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, thirteen have issued a buy rating and one has given a strong buy rating to the company. The average 1-year target price among brokers that have issued a report on the stock in the last year is $12.2308.

CMPX has been the topic of a number of research analyst reports. Wall Street Zen upgraded Compass Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, November 8th. Weiss Ratings restated a “sell (d-)” rating on shares of Compass Therapeutics in a report on Wednesday, October 8th. Citizens Jmp assumed coverage on shares of Compass Therapeutics in a research report on Wednesday, December 3rd. They issued a “market outperform” rating and a $10.00 target price for the company. D. Boral Capital restated a “buy” rating and issued a $30.00 target price on shares of Compass Therapeutics in a research note on Wednesday, November 5th. Finally, Citigroup began coverage on shares of Compass Therapeutics in a research note on Wednesday, December 3rd. They issued an “outperform” rating for the company.

Compass Therapeutics Trading Down 0.2%

NASDAQ CMPX opened at $5.37 on Friday. Compass Therapeutics has a 1 year low of $1.33 and a 1 year high of $5.86. The company has a market cap of $955.11 million, a PE ratio of -11.93 and a beta of 1.45. The stock’s 50-day moving average price is $4.86 and its two-hundred day moving average price is $3.80.

Compass Therapeutics (NASDAQ:CMPX) last released its quarterly earnings results on Wednesday, November 5th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.14) by $0.06. Research analysts forecast that Compass Therapeutics will post -0.36 EPS for the current fiscal year.

Institutional Trading of Compass Therapeutics

Several hedge funds have recently added to or reduced their stakes in CMPX. Charles Schwab Investment Management Inc. boosted its holdings in Compass Therapeutics by 4.1% in the 1st quarter. Charles Schwab Investment Management Inc. now owns 297,880 shares of the company’s stock valued at $566,000 after purchasing an additional 11,689 shares during the period. Nuveen LLC acquired a new position in shares of Compass Therapeutics during the first quarter valued at about $579,000. American Century Companies Inc. bought a new stake in shares of Compass Therapeutics in the first quarter valued at about $140,000. Walleye Capital LLC bought a new stake in shares of Compass Therapeutics in the first quarter valued at about $100,000. Finally, Strs Ohio acquired a new stake in Compass Therapeutics during the first quarter worth about $34,000. Institutional investors own 68.43% of the company’s stock.

About Compass Therapeutics

Compass Therapeutics, Inc is a clinical‐stage biotechnology company dedicated to the discovery and development of novel immuno‐oncology therapies. Headquartered in Cambridge, Massachusetts, the company focuses on engineering monoclonal antibody candidates designed to enhance T cell–mediated anti‐tumor responses. Compass leverages proprietary antibody platforms to identify and optimize biologics that modulate immune checkpoint pathways and the tumor microenvironment.

The company’s lead programs include CTX-471, a bispecific antibody targeting both PD-1 and PD-L1 checkpoints, and DSP107, a CD47‐SIRPα pathway modulator aimed at disrupting “don’t eat me” signals on cancer cells.